Brittany Ragon, MD
Hematology · Charlotte, NCNPI 1598057986
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $19,262 of the $24,662 with a category attached, or 78.1%. 8 manufacturers reported payments, led by Syndax Pharmaceuticals, Inc. at 46.7% of the total. 2025 is the largest year on record at $11,529, more than ten times the $150 reported in 2019.
Across 24 payments — averaging $1027.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Syndax Pharmaceuticals, Inc.$12K
- Genentech, Inc.$7K
- Astellas Pharma US Inc$3K
- Pfizer$3K
- Jazz Pharmaceuticals Inc.$373
- AstraZeneca$150
- plus $182 from 2 others
Across 28 payments — averaging $4401.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$123K
What the payments were for
- Consulting fees$19,26278%
- Speaking & faculty fees$2,85012%
- Travel & lodging$1,3245%
- Food & beverage$1,2265%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Syndax Pharmaceuticals, Inc. | 10 | $11,529 |
| Genentech, Inc. | 3 | $6,655 |
| Astellas Pharma US Inc | 2 | $2,910 |
| Pfizer | 3 | $2,863 |
| Jazz Pharmaceuticals Inc. | 3 | $373 |
| AstraZeneca | 1 | $150 |
| Gilead | 1 | $92 |
| Sanofi | 1 | $90 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,662 in reported general payments places this provider in the 60th percentile of 65 hematology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TasignaNilotinib Hcl | 26 | $504,239 |
| SprycelDasatinib | 16 | $111,441 |
| VenclextaVenetoclax | 14 | $17,220 |
| Cyclosporine ModifiedCyclosporine, Modified | 17 | $3,238 |
| Acyclovir | 59 | $725 |
| Hydroxyurea | 16 | $658 |
| Levofloxacin | 43 | $369 |
| Fluconazole | 13 | $337 |
| Potassium Chloride | 17 | $118 |
| Tramadol Hcl | 17 | $106 |
| Furosemide | 11 | $9 |
Paid to pharmacies, not to this prescriber.
Other hematology in Charlotte
- Ryan JacobsCharlotte$1.5M
- Alan Zausner SkarbnikCharlotte$1.1M
- Raymond ThertulienCharlotte$561K
- Ruben MesaCharlotte$384K
- Michael GrunwaldCharlotte$344K
- Nilay ShahCharlotte$228K
- Peter VoorheesCharlotte$157K
- Patricia KropfCharlotte$122K
- Arielle HeekeCharlotte$88K
- Earle BurgessCharlotte$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.